CH626057A5 - - Google Patents

Download PDF

Info

Publication number
CH626057A5
CH626057A5 CH334576A CH334576A CH626057A5 CH 626057 A5 CH626057 A5 CH 626057A5 CH 334576 A CH334576 A CH 334576A CH 334576 A CH334576 A CH 334576A CH 626057 A5 CH626057 A5 CH 626057A5
Authority
CH
Switzerland
Prior art keywords
oxime
compounds
salts
aminoethyl
pharmaceutically acceptable
Prior art date
Application number
CH334576A
Other languages
German (de)
English (en)
Inventor
Hendricus Bernardus Anto Welle
Volkert Claassen
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of CH626057A5 publication Critical patent/CH626057A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/50Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH334576A 1975-03-20 1976-03-17 CH626057A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (1)

Publication Number Publication Date
CH626057A5 true CH626057A5 (enExample) 1981-10-30

Family

ID=19823424

Family Applications (4)

Application Number Title Priority Date Filing Date
CH334576A CH626057A5 (enExample) 1975-03-20 1976-03-17
CH154081A CH629477A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH154181A CH629761A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH153981A CH629184A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.

Family Applications After (3)

Application Number Title Priority Date Filing Date
CH154081A CH629477A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH154181A CH629761A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH153981A CH629184A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.

Country Status (27)

Country Link
US (1) US4085225A (enExample)
JP (1) JPS6026776B2 (enExample)
AR (2) AR211011A1 (enExample)
AT (1) AT340895B (enExample)
AU (1) AU505358B2 (enExample)
BE (1) BE839744A (enExample)
CA (1) CA1076142A (enExample)
CH (4) CH626057A5 (enExample)
DD (1) DD128332A5 (enExample)
DE (1) DE2610886A1 (enExample)
DK (1) DK144942C (enExample)
ES (1) ES446192A1 (enExample)
FI (1) FI61875C (enExample)
FR (1) FR2304336A1 (enExample)
GB (1) GB1535226A (enExample)
GR (1) GR60052B (enExample)
HU (1) HU171030B (enExample)
IE (1) IE43768B1 (enExample)
IL (1) IL49238A (enExample)
IT (1) IT1063064B (enExample)
MX (1) MX9203723A (enExample)
NL (1) NL7503310A (enExample)
PL (3) PL101951B1 (enExample)
SE (1) SE410312B (enExample)
SU (3) SU635867A3 (enExample)
YU (1) YU39345B (enExample)
ZA (1) ZA761434B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
IN182588B (enExample) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (enExample) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
WO2001080845A2 (en) 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
BRPI0613664B1 (pt) 2005-07-19 2021-08-24 Azevan Pharmaceuticals, Inc Compostos antagonistas de beta-lactamil fenilalanina, cisteína e serina vasopressina, composição farmacêutica que compreende ditos compostos e usos terapêuticos dos mesmos
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス,インコーポレイティド 神経発生のgaba受容体媒介調節
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011050198A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AU2010328186B2 (en) 2009-12-08 2014-12-18 Case Western Reserve University Compounds and methods of treating ocular disorders
PL3351104T3 (pl) 2010-07-01 2021-06-14 Azevan Pharmaceuticals, Inc. Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych
US20140010883A1 (en) 2011-03-17 2014-01-09 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
PT2981518T (pt) * 2013-04-03 2021-06-04 Zcl Chemicals Ltd Um processo melhorado para a preparação de maleato de fluvoxamina
EP3104847B8 (en) 2014-02-07 2020-12-30 Támogatott Kutatócsoportok Irodája Novel use of sigma-1 receptor agonist compounds
SG11201608064WA (en) 2014-03-28 2016-10-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
PH12018501903B1 (en) 2016-03-10 2023-03-17 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
ES2926179T3 (es) 2016-11-24 2022-10-24 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Utilización de composiciones para la conservación de órganos/tejidos
CA3075759A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
IE43768B1 (en) 1981-05-20
DE2610886A1 (de) 1976-10-07
SE7603341L (sv) 1976-09-21
HU171030B (hu) 1977-10-28
CA1076142A (en) 1980-04-22
SU635867A3 (ru) 1978-11-30
JPS6026776B2 (ja) 1985-06-25
FI61875B (fi) 1982-06-30
FI760699A7 (enExample) 1976-09-21
ATA195476A (de) 1977-05-15
CH629761A5 (de) 1982-05-14
DK144942C (da) 1982-12-06
FR2304336A1 (fr) 1976-10-15
AU1214776A (en) 1977-09-22
PL100614B1 (pl) 1978-10-31
AT340895B (de) 1978-01-10
NL7503310A (nl) 1976-09-22
ES446192A1 (es) 1977-10-01
DE2610886C2 (enExample) 1987-09-24
ZA761434B (en) 1977-10-26
PL100052B1 (pl) 1978-08-31
SU645559A3 (ru) 1979-01-30
DD128332A5 (de) 1977-11-09
DK115976A (da) 1976-09-21
SE410312B (sv) 1979-10-08
AR211011A1 (es) 1977-10-14
MX9203723A (es) 1992-07-01
FI61875C (fi) 1982-10-11
AU505358B2 (en) 1979-11-15
AR211153A1 (es) 1977-10-31
CH629477A5 (de) 1982-04-30
GB1535226A (en) 1978-12-13
CH629184A5 (de) 1982-04-15
IE43768L (en) 1976-09-20
YU39345B (en) 1984-10-31
BE839744A (fr) 1976-09-20
SU620206A3 (ru) 1978-08-15
PL101951B1 (pl) 1979-02-28
GR60052B (en) 1978-04-04
YU71476A (en) 1982-10-31
DK144942B (da) 1982-07-12
FR2304336B1 (enExample) 1979-09-28
IL49238A0 (en) 1976-05-31
IT1063064B (it) 1985-02-11
US4085225A (en) 1978-04-18
JPS51125345A (en) 1976-11-01
IL49238A (en) 1978-08-31

Similar Documents

Publication Publication Date Title
CH626057A5 (enExample)
CH616676A5 (enExample)
DE2434911C2 (de) Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen
CH615677A5 (enExample)
DE2305092C2 (enExample)
CH626062A5 (enExample)
CH622501A5 (enExample)
DE2610679C2 (de) Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
CH626056A5 (enExample)
DE2353160C2 (de) 5-Phenyl-2,3-dihydro-1H-1,4-benzodiazepine, ihre Säureadditionssalze und diese Verbindungen enthaltende Arzneimittel
DE2034588C3 (de) 6,7-Dimethoxy-4-benzylisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
DE2348577A1 (de) L-amino-4-phenyltetralin-derivate und diese enthaltende pharmazeutische zubereitung
DE2421549A1 (de) Naphthalinderivate, verfahren zu ihrer herstellung und arzneimittel
DE2615129A1 (de) Tripeptide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE69621706T2 (de) Verwendung von Piperazinverbindungen als narkotische Antagonisten
DE2003353B2 (de) Phenylisopropylaminoäthanol-Derivate, deren Herstellungsverfahren und Arzneimittel auf deren Basis
DE2538593C3 (de) m-Trifluormethylthio-phenäthylaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2810482A1 (de) 1-phenyl-2- eckige klammer auf (n-alkyl)-amino eckige klammer zu -propan-1,3-diole, solche enthaltende arzneimittel und verfahren zur herstellung derselben
AT278785B (de) Verfahren zur Herstellung von neuen Piperidinderivaten und ihren Salzen
DE2022790C3 (de) 10-Methyl-5-[ (4-Methylpiperazino)-acetyl J-5,10dihydro-llH-dibenzo [b,e ] [1,4 ] diazepin-11-on, ein Verfahren zu dessen Herstellung sowie dieses enthaltende Arzneimittel
DE1951614B2 (de) Substituierte Benzylalkohol, deren physiologisch verträgliche Salze, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2610302A1 (de) Antidepressive verbindungen
CH454147A (de) Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2538593B2 (de) M-trifluormethylthio-phenaethylaminderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CH511847A (de) Verfahren zur Herstellung von neuen serumlipoidvermindernden Pyridinderivaten

Legal Events

Date Code Title Description
PL Patent ceased
SPCF Supplementary protection certificate filed

Free format text: IKS 44603/830713, 960221

SPCG Supplementary protection certificate granted

Free format text: IKS 44603/830713, 960221, EXPIRES:19980713